ME02932B - Kombinovana terapija koja uključuje antitela protiv klaudina 18.2 za lečenje kancera - Google Patents

Kombinovana terapija koja uključuje antitela protiv klaudina 18.2 za lečenje kancera

Info

Publication number
ME02932B
ME02932B MEP-2017-187A MEP2017187A ME02932B ME 02932 B ME02932 B ME 02932B ME P2017187 A MEP2017187 A ME P2017187A ME 02932 B ME02932 B ME 02932B
Authority
ME
Montenegro
Prior art keywords
cancer
treatment
combination therapy
antibodies against
therapy involving
Prior art date
Application number
MEP-2017-187A
Other languages
German (de)
English (en)
French (fr)
Inventor
Ugur Sahin
Özlem Türeci
Rita Mitnacht-Kraus
Stefan Denis Jacobs
Magdalena Jadwiga Utsch
Cornelia Adriana Maria Heinz
Christiane Regina Stadler
Original Assignee
Ganymed Pharmaceuticals Gmbh
Tron Translationale Onkologie An Der Univ Der Johannes Gutenberg Univ Mainz Gemeinnuetzige Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=52544200&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ME02932(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from PCT/EP2012/002210 external-priority patent/WO2013174403A1/en
Application filed by Ganymed Pharmaceuticals Gmbh, Tron Translationale Onkologie An Der Univ Der Johannes Gutenberg Univ Mainz Gemeinnuetzige Gmbh filed Critical Ganymed Pharmaceuticals Gmbh
Publication of ME02932B publication Critical patent/ME02932B/me

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3046—Stomach, Intestines

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Cell Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
MEP-2017-187A 2012-05-23 2013-05-21 Kombinovana terapija koja uključuje antitela protiv klaudina 18.2 za lečenje kancera ME02932B (me)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
PCT/EP2012/002210 WO2013174403A1 (en) 2012-05-23 2012-05-23 Combination therapy involving antibodies against claudin 18.2 for treatment of cancer
EP13724523.9A EP2852408B1 (en) 2012-05-23 2013-05-21 Combination therapy involving antibodies against claudin 18.2 for treatment of cancer
PCT/EP2013/001504 WO2013174510A1 (en) 2012-05-23 2013-05-21 Combination therapy involving antibodies against claudin 18.2 for treatment of cancer

Publications (1)

Publication Number Publication Date
ME02932B true ME02932B (me) 2018-04-20

Family

ID=52544200

Family Applications (1)

Application Number Title Priority Date Filing Date
MEP-2017-187A ME02932B (me) 2012-05-23 2013-05-21 Kombinovana terapija koja uključuje antitela protiv klaudina 18.2 za lečenje kancera

Country Status (8)

Country Link
EP (4) EP3254695B1 (me)
CY (2) CY1119549T1 (me)
DK (1) DK3254695T3 (me)
HR (1) HRP20171218T1 (me)
ME (1) ME02932B (me)
PL (2) PL2852408T3 (me)
RS (1) RS56187B1 (me)
SI (1) SI2852408T1 (me)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3254695B1 (en) 2012-05-23 2020-09-09 Astellas Pharma Inc. Combination therapy involving antibodies against claudin 18.2 for treatment of cancer
CA3089653A1 (en) * 2018-03-08 2019-09-12 Phanes Therapeutics, Inc. Anti-claudin 18.2 antibodies and uses thereof
US20220033491A1 (en) 2018-09-30 2022-02-03 Cafa Therapeutics Limited Combination therapy of cldn18 antibody and chemotherapy drugs
CN109762067B (zh) * 2019-01-17 2020-02-28 北京天广实生物技术股份有限公司 结合人Claudin 18.2的抗体及其用途
CN111978402B (zh) * 2019-05-24 2022-06-28 三优生物医药(上海)有限公司 新型cldn18.2结合分子
CN111704669B (zh) * 2020-07-13 2022-05-13 北京凯因科技股份有限公司 一种用于治疗晚期胃癌的抗cldn18全人源化抗体
CN112480248B (zh) * 2020-11-24 2023-05-05 三优生物医药(上海)有限公司 与cld18a2特异性结合的分子

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8601597D0 (en) 1986-01-23 1986-02-26 Wilson R H Nucleotide sequences
GB8717430D0 (en) 1987-07-23 1987-08-26 Celltech Ltd Recombinant dna product
GB8809129D0 (en) 1988-04-18 1988-05-18 Celltech Ltd Recombinant dna methods vectors and host cells
ES2295228T3 (es) 2000-11-30 2008-04-16 Medarex, Inc. Roedores transcromosomicos transgenicos para la preparacion de anticuerpos humanos.
US7754208B2 (en) 2001-01-17 2010-07-13 Trubion Pharmaceuticals, Inc. Binding domain-immunoglobulin fusion proteins
US20030133939A1 (en) 2001-01-17 2003-07-17 Genecraft, Inc. Binding domain-immunoglobulin fusion proteins
PL216630B1 (pl) 2002-10-17 2014-04-30 Genmab As Izolowane ludzkie przeciwciało monoklonalne wiążące ludzki CD20, związane z tym przeciwciałem transfektoma, komórka gospodarza, transgeniczne zwierzę lub roślina, kompozycja, immunokoniugat, cząsteczka bispecyficzna, wektor ekspresyjny, kompozycja farmaceutyczna, zastosowanie medyczne, zestaw oraz przeciwciało antyidiotypowe i jego zastosowanie
EP1997832A1 (en) * 2007-05-29 2008-12-03 Ganymed Pharmaceuticals AG Monoclonal antibodies against Claudin-18 for treatment of cancer
US8445219B2 (en) * 2008-07-25 2013-05-21 Merck Patent Gmbh Method of determination of receptor binding saturation effected by monoclonal antibodies
WO2011090005A1 (ja) * 2010-01-19 2011-07-28 協和発酵キリン株式会社 大腸癌の治療用医薬および治療方法
EP3254695B1 (en) 2012-05-23 2020-09-09 Astellas Pharma Inc. Combination therapy involving antibodies against claudin 18.2 for treatment of cancer

Also Published As

Publication number Publication date
CY1119549T1 (el) 2018-03-07
EP2852408B1 (en) 2017-05-17
EP3791896B1 (en) 2024-01-10
EP4364756A2 (en) 2024-05-08
PL2852408T3 (pl) 2017-12-29
PL3254695T3 (pl) 2021-04-06
CY1123593T1 (el) 2022-03-24
SI2852408T1 (sl) 2017-10-30
EP3791896A1 (en) 2021-03-17
RS56187B1 (sr) 2017-11-30
EP2852408A1 (en) 2015-04-01
EP3254695A1 (en) 2017-12-13
HRP20171218T1 (hr) 2017-10-20
DK3254695T3 (da) 2020-11-30
EP3254695B1 (en) 2020-09-09

Similar Documents

Publication Publication Date Title
IL276434A (en) Combined treatment involving antibodies against claudin 18.2 for the treatment of cancer
IL279330A (en) Combined treatment including antibodies against Claudin 18.2 for the treatment of cancer
HK1219486A1 (zh) 用於治療癌症的涉及抗密蛋白 的抗體的療法
HK1213925A1 (zh) 用於治療癌症的涉及抗密蛋白 抗體的組合療法
RS56187B1 (sr) Kombinovana terapija koja uključuje antitela protiv klaudina 18.2 za lečenje kancera
RS63738B1 (sr) Kombinovana terapija koja uključuje antitela protiv klaudina 18.2 za lečenje kancera
PL2976360T3 (pl) Terapia obejmująca przeciwciała przeciwko klaudynie 18.2 do leczenia nowotworu złośliwego